Self-Antigen Vaccination for Alpha-Synuclein Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease primarily address motor symptoms and lack disease-modifying properties, with no available agent capable of altering the disease progression effectively.
Innovation Solution
A method for vaccination against self-antigens, specifically using a peptide-KLH conjugate that mimics the C-terminal region of human alpha-synuclein, administered in a priming and boosting regimen to elicit a specific immune response without triggering autoimmunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a vaccine targets a self-protein to induce immune response, then the desired structure is targeted effectively, but autoimmunity occurs as a side effect
Solution Approach 1:
The self-protein antigen is divided into specific peptide epitopes (such as Aβ1-42, aSyn106-130, tau181-205) that are conjugated to carrier proteins. This segmentation allows the vaccine to target specific pathological structures while avoiding cross-reactivity with native self-proteins, thereby inducing immune response against the disease-causing forms without triggering autoimmunity against normal physiological proteins
Solution Approach 2:
Carrier proteins (such as KLH, BSA, or CRM197) are used as intermediaries to present the self-protein peptide epitopes to the immune system. These carriers facilitate the induction of immune response against the peptide epitopes while their foreign nature to the human immune system helps prevent activation of autoreactive T cells, thus mediating between the need to target self-protein and the risk of autoimmunity
2Object-generated harmful factors
If the antigenic epitope is made short to prevent T cell activation, then autoimmunity is reduced, but the ability to serve as an antibody epitope is compromised
Solution Approach 1:
The vaccine design applies local quality by selecting specific peptide sequences with particular properties: they are short enough (typically 15-30 amino acids) to minimize T cell activation and autoimmunity risk, yet contain specific structural features (such as hydrophobic regions, beta-sheet forming sequences) that allow them to serve as effective antibody epitopes for recognizing pathological aggregates of the self-protein
3Ease of operation
If current treatments address motor symptoms with dopaminergic strategies, then symptomatic benefit is achieved, but disease progression is not modified and side effects increase
Solution Approach 1:
Instead of treating symptoms with dopaminergic agents, the vaccine approach inverts the strategy by targeting the underlying pathological cause (misfolded self-protein aggregates) to induce immune clearance. This inversion shifts from symptomatic management to disease-modifying therapy, addressing the root cause rather than the manifestations
Data Source
AI summary
Disclosed is a method for vaccination against a self-antigen in a human patient wherein a dose with an effective amount of a self-antigen is administered to the patient to elicit a primary immune response, characterised in that the patient is subjected to a boost administration of said self-antigen, wherein the amount of the self-antigen in the dose for the boost administration is higher than the amount of the self-antigen in the dose used in the administration for the primary immune response.